HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplement Industry Slams New York’s Reasons To Age-Restrict Sales, Expects Other States To Follow

Executive Summary

Sales of supplements and OTC drugs labeled for weight loss and bodybuilding supplements in New York will be prohibited to consumers younger than 18 starting in April 2024. “Once one state does it, what you see is that other states sort of look at that,” says CRN CEO Steve Mister.

You may also be interested in...

NPA Complaint For Preemption Argues New York Swings Wildly With Age-Restricted Sales Law

New York law crosses so many federal regulations it would also affect Rx drug sales while allowing consumers to file complaints alleging businesses violate the law, NPA argues in complaint filed in federal court in New York City.

State Lawmakers Likely To Deal Questions About Oral Phenylephrine Into 2024 Legislation Deck

State government authority is limited to make changes concerning OTC sales, including oral products with phenylephrine. “As we've learned in the past, that hasn't stopped them before. We're going to be monitoring this very closely going into next year,” says CHPA state legislature lobby chief Carlos Gutierrez.

States’ Restrictions On Sales Of Weight Loss OTCs, Supplements Stalled By Vetoes, Lobbying

States’ efforts on prohibiting sales to minors of OTC diet drugs as well as weight loss and bodybuilding supplements to minors didn’t advance in 2022, setting stage for more showdowns in 2023.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts